Abstract
It is not known whether increased breast cancer risk caused by menopausal hormone therapy (HT) depends on body mass patterns through life. In a prospective study of 483,241 Norwegian women aged 50–69 years at baseline, 7656 women developed breast cancer during follow-up (2006–2013). We combined baseline information on recalled body mass in childhood/adolescence and current (baseline) body mass index (BMI) to construct mutually exclusive life-course body mass patterns. We assessed associations of current HT use with breast cancer risk according to baseline BMI and life-course patterns of body mass, and estimated relative excess risk due to interaction (RERI). Within all levels of baseline BMI, HT use was associated with increased risk. Considering life-course body mass patterns as a single exposure, we used women who “remained at normal weight” through life as the reference, and found that being “overweight as young” was associated with lower risk (hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.76–0.94), whereas women who “gained weight” had higher risk (HR 1.20, 95% CI 1.12–1.28). Compared to never users of HT who were “overweight as young”, HT users who either “remained at normal weight” or “gained weight” in adulthood were at higher risk than expected when adding the separate risks (RERI 0.52, 95% CI 0.09–0.95, and RERI 0.37, 95% CI − 0.07–0.80), suggesting effect modification. Thus, we found that women who remain at normal weight or gain weight in adulthood may be more susceptible to the risk increasing effect of HT compared to women who were overweight as young.
Similar content being viewed by others
References
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047–59.
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–53.
Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.
Moyer VA. U.S. preventive task force. medications to decrease the risk for breast cancer in women: recommendations from the U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(10):698–708.
Cui Y, Deming-Halverson SL, Beeghly-Fadiel A, et al. Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk. Clin Cancer Res. 2014;20(5):1169–78.
Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013;105(18):1365–72.
Rosenberg L, Palmer JR, Wise LA, Adams-Campbell LL. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med. 2006;166(7):760–5.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4):485–91.
Reeves GK, Beral V, Green J, Gathani T, Bull D, Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006;7(11):910–8.
Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes—results from a large nested case-control study in a national screening program. Breast Cancer Res. 2017;19(1):10.
Rothman KJ, Greenland S, Lash TL. Concepts of Interaction. In: Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 71–83.
Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol. 1980;112(4):467–70.
Richardson DB, Kaufman JS. Estimation of the relative excess risk due to interaction and associated confidence bounds. Am J Epidemiol. 2009;169(6):756–60.
Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3):421–30.
Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278(17):1407–11.
Magnusson C, Baron J, Persson I, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998;76(1):29–34.
Willett WC, Browne ML, Bain C, et al. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol. 1985;122(5):731–40.
Baer HJ, Colditz GA, Rosner B, et al. Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study. Breast Cancer Res. 2005;7(3):R314–25.
Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 2010;171(11):1183–94.
Fagherazzi G, Guillas G, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S. Body shape throughout life and the risk for breast cancer at adulthood in the French E3N cohort. Eur J Cancer Prev. 2013;22(1):29–37.
Bandera EV, Chandran U, Zirpoli G, et al. Body size in early life and breast cancer risk in African American and European American women. Cancer Causes Control. 2013;24(12):2231–43.
Hilakivi-Clarke L, Forsen T, Eriksson JG, et al. Tallness and overweight during childhood have opposing effects on breast cancer risk. Br J Cancer. 2001;85(11):1680–4.
Warner ET, Hu R, Collins LC, et al. Height and body size in childhood, adolescence, and young adulthood and breast cancer risk according to molecular subtype in the nurses’ health studies. Cancer Prev Res (Phila). 2016;9(9):732–8.
Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TI. Growth patterns and the risk of breast cancer in women. Int J Gynecol Cancer. 2006;16(Suppl 2):569–75.
Hofvind S, Tsuruda KM, Mangerud G, Zerener G. The Norwegian Breast Cancer Screening Program, 1996-2016: Celebrating 20 years of organised mammographic screening. In: Cancer in Norway 2016—Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, Oslo, Norway. 2017. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2016/mammo_cin2016_special_issue_web.pdf. Accessed 21 Feb 2018.
Tsuruda KM, Sagstad S, Sebuodegard S, Hofvind S. Validity and reliability of self-reported health indicators among women attending organized mammographic screening. Scand J Public Health. 2018. https://doi.org/10.1177/1403494817749393
Ritte R, Lukanova A, Tjonneland A, et al. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer. 2013;132(11):2619–29.
Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology. 2012;13(11):1141–51.
Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.
Hofvind S, Sagstad S, Selbuødegård S, Holen ÅS. Mammografiprogrammet—Resultater fra prosessindikatorer, 2006-2013/14. Oslo: Kreftregisteret; 2015.
Rockhill B, Colditz GA, Rosner B. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol. 2000;151(4):404–8.
Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998;147(8):718–21.
VanderWeele TJ. On the distinction between interaction and effect modification. Epidemiology. 2009;20(6):863–71.
Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41(2):514–20.
Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol. 2005;20(7):575–9.
Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. 1992;3(5):452–6.
Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol. 2007;17(3):227–36.
VanderWeele T. Explanation in causal inference: methods for mediation and interaction. Oxford: Oxford University Press; 2015.
Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the european prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2004;111(5):762–71.
Wu AH, Yu MC, Tseng CC, Pike MC. Body size, hormone therapy and risk of breast cancer in Asian-American women. Int J Cancer. 2007;120(4):844–52.
Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012;14(3):R76.
Canchola AJ, Anton-Culver H, Bernstein L, et al. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control. 2012;23(3):473–85.
Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 2006;8(1):R11.
Hvidtfeldt UA, Tjonneland A, Keiding N, et al. Risk of breast cancer in relation to combined effects of hormone therapy, body mass index, and alcohol use, by hormone-receptor status. Epidemiology. 2015;26(3):353–61.
Lahmann PH, Schulz M, Hoffmann K, et al. Long-term weight change and breast cancer risk: the European prospective investigation into cancer and nutrition (EPIC). Br J Cancer. 2005;93(5):582–9.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
Lund E, Mode N, Waaseth M, Thalabard JC. Overdiagnosis of breast cancer in the Norwegian breast cancer screening program estimated by the Norwegian women and cancer cohort study. BMC Cancer. 2013;13:614.
Costas L, Sequera VG, Quesada P, et al. Hormonal contraception and postmenopausal hormone therapy in Spain: time trends and patterns of use. Menopause. 2015;22(10):1138–46.
Cairns BJ, Liu B, Clennell S, et al. Lifetime body size and reproductive factors: comparisons of data recorded prospectively with self reports in middle age. BMC Med Res Methodol. 2011;11:7.
Ahlgren M, Melbye M, Wohlfahrt J, Sorensen TI. Growth patterns and the risk of breast cancer in women. N Engl J Med. 2004;351(16):1619–26.
Samimi G, Colditz GA, Baer HJ, Tamimi RM. Measures of energy balance and mammographic density in the Nurses’ Health Study. Breast Cancer Res Treat. 2008;109(1):113–22.
Andersen ZJ, Baker JL, Bihrmann K, Vejborg I, Sorensen TI, Lynge E. Birth weight, childhood body mass index, and height in relation to mammographic density and breast cancer: a register-based cohort study. Breast Cancer Res. 2014;16(1):R4.
Bertrand KA, Baer HJ, Orav EJ, et al. Body fatness during childhood and adolescence and breast density in young women: a prospective analysis. Breast Cancer Res. 2015;17:95.
McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women’s Health Initiative randomized trial. J Natl Cancer Inst. 2005;97(18):1366–76.
Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95(1):30–7.
Couto E, Qureshi SA, Hofvind S, et al. Hormone therapy use and mammographic density in postmenopausal Norwegian women. Breast Cancer Res Treat. 2012;132(1):297–305.
Rice MS, Bertrand KA, VanderWeele TJ, et al. Mammographic density and breast cancer risk: a mediation analysis. Breast Cancer Res. 2016;18(1):94.
Ahlbom A, Alfredsson L. Interaction: a word with two meanings creates confusion. Eur J Epidemiol. 2005;20(7):563–4.
Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–92.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.
Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–41.
Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol. 2002;20(3):699–706.
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–27.
Chlebowski RT, Anderson GL, Aragaki AK, Prentice R. Breast cancer and menopausal hormone therapy by race/ethnicity and body mass index. J. Natl. Cancer Inst. 2016;108(2).
Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG. Hormone therapy and breast cancer: what factors modify the association? Menopause. 2006;13(2):178–84.
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328–32.
Lahmann PH, Lissner L, Gullberg B, Olsson H, Berglund G. A prospective study of adiposity and postmenopausal breast cancer risk: the Malmo Diet and Cancer Study. Int J Cancer. 2003;103(2):246–52.
Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(7):593–600.
Beral V, Reeves G, Bull D, Green J, Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296–305.
Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999;81(3):339–44.
Beral V, Banks E, Reeves G, Wallis M. Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet. 1997;349(9058):1103–4.
Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3150–60.
White KK, Park SY, Kolonel LN, Henderson BE, Wilkens LR. Body size and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2012;131(5):E705–16.
Salagame U, Banks E, Sitas F, Canfell K. Menopausal hormone therapy use and breast cancer risk in Australia: findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study. Int J Cancer. 2016;138(8):1905–14.
Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165(10):1187–98.
Acknowledgements
We are indebted to the women who participated in the Norwegian Breast Cancer Screening Program (NBCSP) and provided the information that is used in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
All authors declares that they have no conflicts of interest.
Additional information
Disclaimer The study has used data from the Cancer Registry of Norway. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Cancer Registry of Norway is intended nor should be inferred.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Sandvei, M.S., Vatten, L.J., Bjelland, E.K. et al. Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life. Eur J Epidemiol 34, 267–278 (2019). https://doi.org/10.1007/s10654-018-0431-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-018-0431-7